Pristimerin: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
Line 1: Line 1:
{{Infobox chemical
 
{{Infobox drug
| name = Pristimerin
| name = Pristimerin
| image = Pristimerin_structure.png
| image = <!-- Image file name -->
| image_size = 250px
| width = <!-- Image width -->
| image_alt = Chemical structure of Pristimerin
| alt = <!-- Image alt text -->
| IUPAC_name = (3β)-3-Hydroxy-6-oxoolean-12-en-28-oic acid
| caption = <!-- Image caption -->
| other_names = Maytenfolic acid
| cas_number = 1258-84-0
| CAS_number = 1258-84-0
| pubchem = 73568
| molecular_formula = C30H40O4
| chemspiderid = 66213
| chemical_formula = C<sub>30</sub>H<sub>40</sub>O<sub>4</sub>
| molar_mass = 464.64 g/mol
| molar_mass = 464.64 g/mol
}}
}}


'''Pristimerin''' is a naturally occurring [[triterpenoid]] compound found in various plant species, particularly within the [[Celastraceae]] family. It has garnered significant interest in the scientific community due to its potential [[pharmacological]] properties, including [[anti-cancer]], [[anti-inflammatory]], and [[antioxidant]] effects.
'''Pristimerin''' is a naturally occurring [[triterpenoid]] compound found in various plant species, particularly in the [[Celastraceae]] family. It has been studied for its potential [[pharmacological]] properties, including [[anti-cancer]], [[anti-inflammatory]], and [[antioxidant]] effects.


==Chemical Structure and Properties==
== Chemical Structure and Properties ==
Pristimerin is classified as a [[triterpenoid]], a type of chemical compound composed of three [[terpene]] units, resulting in a structure with 30 carbon atoms. Its IUPAC name is (3β)-3-Hydroxy-6-oxoolean-12-en-28-oic acid, and it has a molecular formula of C30H40O4. The compound is characterized by a pentacyclic structure, which is common among triterpenoids, and includes functional groups such as a hydroxyl group and a carboxylic acid group.
Pristimerin is classified as a [[quinonemethide triterpenoid]], characterized by its unique chemical structure that includes a [[quinone]] methide moiety. The [[molecular formula]] of Pristimerin is C<sub>30</sub>H<sub>40</sub>O<sub>4</sub>, and it has a [[molar mass]] of 464.64 g/mol.


==Sources==
== Sources ==
Pristimerin is primarily isolated from plants in the Celastraceae family, such as ''Maytenus ilicifolia'' and ''Tripterygium wilfordii''. These plants have been traditionally used in [[herbal medicine]] for their therapeutic properties.
Pristimerin is primarily extracted from plants belonging to the Celastraceae family, such as ''[[Maytenus]]'' and ''[[Tripterygium]]'' species. These plants have been traditionally used in [[herbal medicine]] for their therapeutic properties.


==Pharmacological Activities==
== Pharmacological Activities ==
Pristimerin has been the subject of numerous studies due to its diverse biological activities:
=== Anti-Cancer Activity ===
Pristimerin has shown promising [[anti-cancer]] activity in various [[in vitro]] and [[in vivo]] studies. It is believed to induce [[apoptosis]] in cancer cells by targeting multiple [[signaling pathways]], including the [[NF-κB]] and [[PI3K/Akt]] pathways. Pristimerin has been studied in the context of [[breast cancer]], [[prostate cancer]], and [[leukemia]].


===Anti-Cancer Activity===
=== Anti-Inflammatory Effects ===
Pristimerin has shown promising anti-cancer properties in various [[in vitro]] and [[in vivo]] studies. It is believed to induce [[apoptosis]] in cancer cells through multiple mechanisms, including the inhibition of the [[proteasome]] and the activation of [[caspases]]. Additionally, pristimerin has been reported to inhibit the [[NF-κB]] signaling pathway, which plays a crucial role in cancer cell survival and proliferation.
The compound exhibits significant [[anti-inflammatory]] effects by inhibiting the production of [[pro-inflammatory cytokines]] and mediators. It has been shown to suppress the activation of [[NF-κB]], a key transcription factor involved in the inflammatory response.


===Anti-Inflammatory Effects===
=== Antioxidant Properties ===
The compound exhibits significant anti-inflammatory effects by modulating the production of [[cytokines]] and inhibiting the activity of [[cyclooxygenase]] enzymes. These properties make pristimerin a potential candidate for the treatment of inflammatory diseases.
Pristimerin also possesses [[antioxidant]] properties, which help in reducing [[oxidative stress]] by scavenging [[free radicals]]. This activity contributes to its potential therapeutic effects in preventing [[chronic diseases]] associated with oxidative damage.


===Antioxidant Properties===
== Potential Applications ==
Pristimerin also acts as an antioxidant, scavenging [[free radicals]] and reducing oxidative stress. This activity contributes to its protective effects against cellular damage and aging.
Due to its diverse pharmacological activities, Pristimerin is being explored for potential applications in [[cancer therapy]], [[inflammatory diseases]], and as a [[neuroprotective]] agent. However, further research is needed to fully understand its mechanisms of action and to develop effective therapeutic formulations.


==Potential Applications==
== Safety and Toxicity ==
Due to its pharmacological properties, pristimerin is being explored for potential applications in the treatment of various diseases, including cancer, inflammatory disorders, and neurodegenerative diseases. However, further research is needed to fully understand its mechanisms of action and to develop effective therapeutic formulations.
While Pristimerin has shown potential benefits, its [[safety profile]] and [[toxicity]] need to be thoroughly evaluated in [[clinical trials]]. Current studies suggest that it may have a narrow [[therapeutic window]], and its effects on [[human health]] require careful assessment.


==Safety and Toxicity==
== See Also ==
While pristimerin has shown therapeutic potential, its safety profile is not yet fully established. Some studies have reported cytotoxic effects at high concentrations, highlighting the need for careful dosage considerations in potential therapeutic applications.
 
==Also see==
* [[Triterpenoid]]
* [[Triterpenoid]]
* [[Celastraceae]]
* [[Celastraceae]]
* [[Apoptosis]]
* [[Apoptosis]]
* [[Proteasome]]
* [[NF-κB]]
* [[NF-κB]]


{{Triterpenoids}}
== References ==
{{Phytochemicals}}
<references />
 
== External Links ==
* [PubChem Entry for Pristimerin](https://pubchem.ncbi.nlm.nih.gov/compound/Pristimerin)


[[Category:Triterpenoids]]
[[Category:Triterpenoids]]
[[Category:Phytochemicals]]
[[Category:Pharmacology]]
[[Category:Antioxidants]]
[[Category:Natural products]]
[[Category:Anti-inflammatory agents]]
[[Category:Anti-cancer agents]]

Latest revision as of 20:45, 30 December 2024


Pristimerin
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Pristimerin is a naturally occurring triterpenoid compound found in various plant species, particularly in the Celastraceae family. It has been studied for its potential pharmacological properties, including anti-cancer, anti-inflammatory, and antioxidant effects.

Chemical Structure and Properties[edit]

Pristimerin is classified as a quinonemethide triterpenoid, characterized by its unique chemical structure that includes a quinone methide moiety. The molecular formula of Pristimerin is C30H40O4, and it has a molar mass of 464.64 g/mol.

Sources[edit]

Pristimerin is primarily extracted from plants belonging to the Celastraceae family, such as Maytenus and Tripterygium species. These plants have been traditionally used in herbal medicine for their therapeutic properties.

Pharmacological Activities[edit]

Anti-Cancer Activity[edit]

Pristimerin has shown promising anti-cancer activity in various in vitro and in vivo studies. It is believed to induce apoptosis in cancer cells by targeting multiple signaling pathways, including the NF-κB and PI3K/Akt pathways. Pristimerin has been studied in the context of breast cancer, prostate cancer, and leukemia.

Anti-Inflammatory Effects[edit]

The compound exhibits significant anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and mediators. It has been shown to suppress the activation of NF-κB, a key transcription factor involved in the inflammatory response.

Antioxidant Properties[edit]

Pristimerin also possesses antioxidant properties, which help in reducing oxidative stress by scavenging free radicals. This activity contributes to its potential therapeutic effects in preventing chronic diseases associated with oxidative damage.

Potential Applications[edit]

Due to its diverse pharmacological activities, Pristimerin is being explored for potential applications in cancer therapy, inflammatory diseases, and as a neuroprotective agent. However, further research is needed to fully understand its mechanisms of action and to develop effective therapeutic formulations.

Safety and Toxicity[edit]

While Pristimerin has shown potential benefits, its safety profile and toxicity need to be thoroughly evaluated in clinical trials. Current studies suggest that it may have a narrow therapeutic window, and its effects on human health require careful assessment.

See Also[edit]

References[edit]

<references />

External Links[edit]